The role of BRCA1 in non-small cell lung cancer

被引:7
|
作者
Gachechiladze, Mariam [1 ]
Skarda, Josef [1 ]
机构
[1] Palacky Univ Olomouc, Fac Med & Dent, Dept Clin & Mol Pathol, Olomouc, Czech Republic
来源
BIOMEDICAL PAPERS-OLOMOUC | 2012年 / 156卷 / 03期
关键词
BRCA1; non-small cell lung cancer; chemotherapy; RNA EXPRESSION LEVELS; PHASE-III; CISPLATIN; ERCC1; CHEMOTHERAPY; GEMCITABINE; DOCETAXEL; PLATINUM;
D O I
10.5507/bp.2012.049
中图分类号
R318 [生物医学工程];
学科分类号
0831 ;
摘要
Background. BRCA1 (Breast cancer 1) was previously identified as a breast and ovarian cancer susceptibility gene, but recently gained a major scientific interest as a prognostic and/or predictive marker for various tumors, including non-small cell lung cancer (NSCLC), which is the leading cause of cancer related mortality in the world. We aimed to review the role of BRCA1 in NSCLC based on currently available literature. Methods. We performed the literature search in Pubmed database, using key words: BRCA1, non small cell lung cancer, chemotherapy, drug resistance. Articles published in English were selected for review. Results. Research papers are mainly focused on BRCA1 mRNA expression studies in response to DNA damaging chemotherapy. Several articles about genetic and epigenetic changes of BRCA1 in NSCLC were also available. Conclusions. BRCA1 is a multifunctional tumor supressor protein, which plays a key role in essential cellular processes and modulates the cellular response to cytotoxic chemotherapy. With the difference from breast and ovarian cancer, BRCA1 has no role in NSCLC cancerogenesis and mainly discussed as a promising genomic marker for customized chemotherapy in NSCLC patients.
引用
收藏
页码:200 / 203
页数:4
相关论文
共 50 条
  • [31] Frequency and Molecular Characteristics of BRCA1 Mutations in Non-Small Cell Lung Cancer from East Asian Patients
    Huang, Y.
    Xu, C.
    Wang, W.
    Zhang, Q.
    Zhuang, W.
    Zhu, Y.
    Huang, Y.
    Chen, G.
    Fang, M.
    Lv, T.
    Song, Y.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S963 - S964
  • [32] Current treatment paradigms for locally advanced non-small cell lung cancer
    Rigas, James R.
    Kelly, Karen
    JOURNAL OF THORACIC ONCOLOGY, 2007, 2 (06) : S77 - S85
  • [33] Atezolizumab: A novel PD-L1 inhibitor in cancer therapy with a focus in bladder and non-small cell lung cancers
    Krishnamurthy, A.
    Jimeno, A.
    DRUGS OF TODAY, 2017, 53 (04) : 217 - 237
  • [34] The Emerging Role of Radiotherapy in Oligoprogressive Non-Small Cell Lung Cancer
    Tam, Andrew
    Eustace, Nicholas
    Kassardjian, Ari
    West, Howard
    Williams, Terence M.
    Amini, Arya
    SURGICAL ONCOLOGY CLINICS OF NORTH AMERICA, 2023, 32 (03) : 497 - 514
  • [35] Gefitinib in non-small cell lung cancer
    Tamura, K
    Fukuoka, M
    EXPERT OPINION ON PHARMACOTHERAPY, 2005, 6 (06) : 985 - 993
  • [36] Anthacyclines in non-small cell lung cancer
    Pronzato, P
    Vigani, A
    Tognoni, A
    Vaira, F
    Canessa, P
    LUNG CANCER, 2001, 34 : S57 - S59
  • [37] Chemotherapy in non-small cell lung cancer: opportunities for advancement
    Akhtari, Mani
    Bernicker, Eric H.
    Teh, Bin S.
    CHINESE JOURNAL OF CANCER, 2016, 35 : 56
  • [38] The cost of non-small cell lung cancer (NSCLC) treatment
    Vergnenegre, A.
    ONCOLOGIE, 2012, 14 (05) : 310 - 315
  • [39] Quality of life in patients with non-small cell lung cancer
    Sarac, Sanja
    Milic, Rade
    Vasiljevic, Mira
    Sarac, Momir
    VOJNOSANITETSKI PREGLED, 2017, 74 (07) : 625 - 632
  • [40] Pemetrexed for Heavily Pretreated Patients With Advanced Non-small Cell Lung Cancer
    Lee, Jih-Hsiang
    Yu, Chong-Jen
    Chen, Kuan-Yu
    Shih, Jin-Yuan
    Lin, Yu-Lin
    Yang, Chih-Hsin
    JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION, 2010, 109 (05) : 338 - 344